MARKET

AKBA

AKBA

Akebia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.16
-0.27
-2.13%
After Hours: 12.16 0 0.00% 16:41 05/22 EDT
OPEN
12.41
PREV CLOSE
12.43
HIGH
12.42
LOW
12.00
VOLUME
689.56K
TURNOVER
--
52 WEEK HIGH
13.17
52 WEEK LOW
2.990
MARKET CAP
1.58B
P/E (TTM)
-5.4881
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AKBA stock price target is 17.29 with a high estimate of 26.00 and a low estimate of 11.00.

EPS

AKBA News

More
Akebia Therapeutics Announces Change to Virtual Annual Meeting of Stockholders
PR Newswire · 4d ago
Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the underwriters of its previously announced public offering, which closed on May 14, 2020, ha
PR Newswire · 6d ago
Akebia announces filing in Japan expanded use of Riona tablets
Seeking Alpha - Article · 05/18 15:24
Akebia Therapeutics Announces Collaboration Partner's Submission of Supplemental New Drug Application for Use of Riona® (ferric citrate hydrate) to Treat Adult Patients with Iron Deficiency Anemia in Japan
PR Newswire · 05/18 13:00
Edited Transcript of AKBA earnings conference call or presentation 5-May-20 12:30pm GMT
Thomson Reuters StreetEvents · 05/16 13:55
Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA).
Zacks · 05/13 15:37
'This $AKBA short report reads dumb to me, like someone drank too much coffee and got overly stimulated for nothing. But I'm willing to listen to a saner interpretation and change my mind' -Tweet From STAT News' Adam Feuerstein
https://twitter.com/adamfeuerstein/status/1260243844039413760
Benzinga · 05/12 16:23
Akebia Therapeutics Shares Tick Lower Following Tweet From Short Seller Muddy Waters 'Our PRTA short opened our eyes to the...world of misleading presentation of biotech trial data. No view / no position on AKBA, but it does raise similar questions'
https://twitter.com/muddywatersre/status/1260226977677500419
Benzinga · 05/12 15:30

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About AKBA

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
More

Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions.